Published February 18 2013 in What's New

Laval, February 18 2013Ergoresearch Ltd (TSXV: ERG), based in Laval and known for its Clinique du pied Équilibre, Orthoconcept and Laboratoire Langelier banners, today proudly announced it has been recognized by the TSX Venture Exchange as one of the 2013 TSX Venture 50® companies. Quebec’s leading manufacturer of “intelligent” foot and specialty orthotics ranks 8th in the Technology and Life Science sector in Canada.

This ranking is set among the 2,258 companies listed on TSX Venture Exchange as of December 31. It gathers a group of strong performing companies in five major industry sectors – including Technology and Life Science – and was determined based on equal weighting of the following measures: market capitalization growth, share price appreciation, trading volume and analyst coverage. 2013 TSX Venture 50 companies have an impressive track record. On average, these companies have delivered a return of 129% in 2012. The shares of these companies also enjoy a highly liquid market with a total of 2.9 billion shares trading over the course of 2012.

“We are proud to be part of this select group of Canadian businesses. This recognition clearly reflects the efforts deployed by our entire team in 2012, as well as the company’s performance during this period of accelerated growth,” stated Ergoresearch president and CEO, Sylvain Boucher. “With the acquisition of Laboratoire Langelier in January 2013 and the OdrA launch, a revolutionary treatment that provides relief from the pain and suffering associated with knee osteoarthritis, we are maintaining our stride and are confident we will double our revenues over the course of the next 12 months.”

“TSX Venture Exchange operates a platform that provides emerging companies with the opportunity to access the capital they need to meet their growth objectives,” said John McCoach, President, TSX Venture Exchange. “We are pleased to present the latest group of companies that have excelled in their sectors.”

About Ergoresearch
Ergoresearch has developed Quebec’s leading network of orthotics clinics, with over 100 corporate and satellite centres under the Clinique du pied Équilibre, Orthoconcept, Podotech and Laboratoire Langelier banners. The leading manufacturer of “intelligent” foot orthotics and specialty orthotics, it is a trend-setter in creating durable medical equipment and software for the orthopedics market. Ergoresearch has developed and commercialized Expert-Fit™, the first robotized custom-fit orthotics manufacturing software program, launched the first Living Lab in Canada and more recently, a new generation of world-patented orthotic device called the OdrA, that revolutionizes the treatment of pain associated with knee osteoarthritis. Ergoresearch Ltd is listed on the Toronto Stock Exchange (TSXV) under the symbol ERG.

This is not an invitation to purchase securities listed on TSX Venture Exchange. TMX Group and its affiliates do not endorse or recommend the referenced securities. Please seek professional advice to evaluate specific securities.

Forward-looking statements
Certain statements in this Press Release contain forward-looking statements and information that may entail certain risks related to uncertainties. Such statements are based on management’s expectations and no assurance can be given that potential future results or circumstances described in the forward looking statements will be achieved or will occur. Such risks factors include, but are not limited to, those related to the Corporation’s ability to finance its activities, competition, ability to negotiate and maintain partnerships, the market acceptance of the said product, fluctuations in operating results, the impact of general economics, industry and market conditions, the ability to recruit and retain qualified employees, the success of research and development programs, fluctuations in cash flow, expectations regarding market demand for particular products, the strength of intellectual property, market dependence on new product development, the trust invested in sub-contractors or their core personnel, as well as other documents containing risks and uncertainties which are put forth every now and then by the firm to various Canadian securities and exchange commissions and made available at

The reader should not give great importance to forward-looking statements as (i) the results may differ from conclusions, predictions or projections contained in such forward-looking statements; and (ii) certain important factors or hypothesis taken into account in reaching conclusions or the preparation of a projection or prediction may prove to be incorrect in fact.

Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or circumstances. All figures are in Canadian dollars, unless otherwise specified.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

– 30 –

Sylvain Boucher, President and CEO − Ergoresearch Ltd
Tel.: 450-973-6700, ext. 213 / sboucher@ergoresearch.

Isabelle Vallée, Director − Communications and Public Relations, Ergoresearch Ltd
Tel.: 450-973-6700, ext. 233 / Cell: 514-377-0485 /

Réalisation Web Sept24